“AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses” published in Blood
January 4, 2018 - AIMM publishes its work on the identification of AML-specific cytotoxic antibodies in Blood
AIMM signs exclusive license and option agreement with Merck & Co., Inc., Kenilworth, NJ, USA on preclinical oncology targets
August 1, 2017 - AIMM signs exclusive license and option agreement with Merck & Co., Inc., Kenilworth, NJ, USA on preclinical oncology targets.
Antibody from AML survivor may prove therapeutic, MDedge
June 27, 2017 - MDedge reports on ASCO 2017 presentation: “Antibody from AML survivor may prove therapeutic”.
Killer antibodies against AML, press conference EHA 2016
June 15, 2016 - At a press conference at EHA 2016, details of our work about the discovery of antibodies that bind specifically to AML cells from patients who are in remission from AML was presented.
MEDI8897 Receives Fast Track Designation
April 9, 2015 - AIMM Therapeutics announced today that its partner Medimmune has received fast track designation from the U.S. Food and Drug Administration (FDA) for the development of MEDI8897.
MEDI8897 Advances Into Phase Ib/IIa Study
March 9, 2015 - MedImmune has initiated phase Ib/IIa clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.
Nature Medicine publication
December 22, 2014 - A Netherlands Cancer Institute (NKI) publication co-authored by AIMM Therapeutics in Nature Medicine reveals that recognition of neo-antigens by CD4+ T cells is a common phenomenon in melanoma.
December 11, 2014 - A bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity
AIMM Therapeutics’ 10 year anniversary symposium
October 3, 2014 - You are cordially invited to our 10 year anniversary symposium on November 20, 2014.
MedImmune Starts Clinical Studies with RSV Antibody
July 2, 2014 - MedImmune has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.
PNAS publication: characterization of group 2 Influenza antibodies
December 11, 2013 - A common solution to group 2 influenza virus neutralization
Nature SciBX reviews D25 guided RSV vaccine study
November 14, 2013 - Science-Business eXchange published an article discussing the recent Science study that used AIMMs D25 anti RSV antibody for vaccine design.
Pre-fusion RSV Antibodies
November 4, 2013 - November 4 – AIMM Therapeutics announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved vaccine against RSV.
PLOS pathogens paper
October 11, 2013 - Infection of host tissues by Staphylococcus aureus and S. epidermidis requires an unusual family of staphylococcal adhesive proteins that contain long stretches of serine-aspartate dipeptide-repeats (SDR).
September 16, 2013 - AIMM Therapeutics acquired an Innovation Credit of € 2,9 million from the Dutch government for one of our R&D projects.
ERC Advanced Grant
August 13, 2013 - AIMMs CSO Hergen Spits received a prestigious ERC Advanced Grant from the European Research Council.
July 30, 2013 - AIMM wil present a Nature webcast on July 31.
Scientific advisory board strengthened with new high profile appointments
June 21, 2013 - Bob Löwenberg (Erasmus MC), John Mendelsohn (MD Anderson), and Hidde Ploegh (Whitehead Institute) to join AIMM Scientific advisory board.
Structure of AIMM’s lead antibody D25 binding revealed
April 25, 2013 - Today Science published the pre-fusion cristal of RSV in complex with AIMMs antibody D25.
Strategic partnership with Cosmo Pharmaceuticals
December 19, 2012 - AIMM Therapeutics in strategic partnership with Cosmo Pharmaceuticals
to combine Cosmo’s extended release technology & AIMM’s high quality antibodies to successfully combat gastrointestinal disease.
New CEO and VP Business Development
November 8, 2012 - AIMM Therapeutics appoints former head Novartis Research Institutes Jan de Vries CEO, and John Womelsdorf VP Business Development
BIO International Convention, Boston
June 15, 2012 - AIMM to present at 2012 BIO International Convention, Boston June, 2012 AIMM will present at the 2012 Bio International Convention in Boston, June 18-21.
Science webinar online
March 23, 2012 - Watch the Science webinar ‘New Approaches for Clonal Selection’ on the Science website.
BIO-Europe Spring 2012
March 13, 2012 - AIMM Therapeutics presents at the BIO-Europe Spring 2012 meeting in Amsterdam.
AIMM to present at Science webinar
March 1, 2012 - AIMM Therapeutics is invited to present in a Science webinar on Wednesday March 21.